Literature DB >> 2482314

mAb KUL/05 identifies a denaturation-resistant determinant shared by class II MHC products DR, DQ and DP.

P Giacomini1, R Tecce, M R Nicotra, B B Cohen, M C Mazzilli, P G Natali.   

Abstract

mAb KUL/05, a novel murine monoclonal antibody, reacts with molecules displaying the typical tissue distribution and molecular profile of class II MHC antigens. An extensive scrutiny employing serological and immunochemical assays on DR homozygous and DR alpha- mutant cell lines has shown that this reagent displays some additional, interesting features, namely mAb KUL/05 (a) binds in a broadly monomorphic fashion to cells of DR1 through seven specificities, (b) recognizes a determinant shared by a large proportion of DR, DQ and DP beta chains from most haplotypes, in both their monomeric and alpha chain-associated forms, and (c) reacts with frozen, acetone-fixed, as well as conventional, formalin-fixed, paraffin embedded tissues. Thus, mAb KUL/05 is likely to represent a useful adjunct for the study of the expression of class II MHC products in normal and pathological tissue specimens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482314     DOI: 10.1111/j.1744-313x.1989.tb00463.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  3 in total

1.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

2.  Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-alpha.

Authors:  P Giacomini; M Mottolese; R Fraioli; M Benevolo; I Venturo; P G Natali
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

3.  Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis.

Authors:  Elisa Tremante; Lory Santarelli; Elisa Lo Monaco; Camilla Sampaoli; Tiziano Ingegnere; Roberto Guerrieri; Marco Tomasetti; Patrizio Giacomini
Journal:  Oncotarget       Date:  2015-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.